Allos Oncologic Efaproxiral “Approvable” Pending Phase III ENRICH Data

FDA followed the recommendations of its Oncology Drugs Advisory Committee in issuing an “approvable” letter. Efaproxiral approval is also conditional on FDA clearance of Allos’ manufacturing facility and forthcoming agency comments on pharmacology, toxicology and chemistry issues.